Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from October 14, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 12, 2026 — +0.1% at the close.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted

$94.50 – $96.00Entry zone — fair-value band

$95.66Published — price the day we called it

$110.96Target — the price the thesis aimed for

$105.65Peak — highest point inside the window, not a realized return

$95.72Window close — end-of-window price, context only

What happened

Partial

Reached 65% of the predicted growth at its peak, without hitting the target.

At window close

+0.1%

realized, from the publication price to the last close inside the window

Peak gain

+10.4%

peak, from the publication price — not a realized return

S&P 500, same window

+5.3%

SPY over the identical days, dividend-adjusted

Window close

$95.72

last close inside the window, ended January 12, 2026

Peak price

$105.65

peak on November 13, 2025 — not a realized return

Days to target

—

The thesis — published October 14, 2025

Predicted growth

+16%

over the measurement window

Target price

$110.96

the price the thesis aimed for

Entry zone

$94.50 – $96.00

the fair-value band we waited for

Price at publication

$95.66

published October 14, 2025

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Boston Scientific is a solid medical-device maker whose stock recently fell more than seemed fair. A respected rating model now labels it a Strong Buy, and Polen Capital just took a new stake, showing serious investor interest. With many sellers likely out, the shares could rebound as people reset positions before earnings. Some worry the price is rich, but near-term odds look tilted toward a bounce.

Primary drivers

Respected model now calls it a Strong Buy, a positive quality signal.
Polen Capital started a new stake, showing fresh confidence from big money.
The stock dropped fast and looks set for a short-term bounce back.
Investors may buy ahead of earnings, nudging the price higher soon.

How it played out

BSX: thesis partly played out, but target was missed

Lyra published BSX at 95.66 on 2025-10-14 with a short-term thesis for 16% growth. The thesis pointed to a Strong Buy model label, a new Polen Capital stake, a fast prior drop, and possible buying ahead of earnings. The target was 110.96.

Inside the window, BSX rose to a peak of 105.65 on 2025-11-13, a 10.4% gain. It stayed below the target and never reached 110.96. By 2026-01-12, it ended at 95.72. The thesis partly played out, but the full target was missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals